ContraFect_LOGO_Web.jpg
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
December 19, 2022 16:30 ET | ContraFect Corporation
YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
December 13, 2022 08:01 ET | ContraFect Corporation
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
November 28, 2022 08:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections
September 12, 2022 07:32 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
September 12, 2022 07:30 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 08:30 ET | ContraFect Corporation
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
August 15, 2022 08:25 ET | ContraFect Corporation
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
July 13, 2022 16:05 ET | ContraFect Corporation
YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including...
ContraFect_LOGO_Web.jpg
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
June 14, 2022 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...